Offer Request Form

Order list is empty

Shikari® (S-ATB) Anti-Bevacizumab ELISA

Enzyme immunoassay for the qualitative determination of specific antibodies to Bevacizumab (Avastin®)  in serum and plasma.

This kit has been especially developed for the qualitative determination of specific antibodies to Bevacizumab in serum and plasma samples.


The Matriks Biotek Antibody to Bevacizumab (Avastin®)* Enzyme-Linked-Immuno-Sorbent-Assay (ELISA) Kit is intended for the quantitative determination of antibodies to Bevacizumab (Avastin) in serum and plasma.

As with all therapeutic proteins, there is a potential for immunogenicity. Accoring to the manufacturers product insert; the incidence of antibody development in patients receiving Avastin has not been adequately determined because the assay sensitivity was inadequate to reliably detect lower titers. Enzyme-linked immunosorbent assays (ELISAs) were performed on sera from approximately 500 patients treated with Avastin, primarily in combination with chemotherapy. High titer human anti-Avastin antibodies were not detected. Immunogenicity data are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Avastin with the incidence of antibodies to other products may be misleading. The Matriks Biotek Antibody to Bevacizumab ELISA Kit can be used for monitoring anti-Bevacizumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures.Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

All SHIKARI® ELISA kits are suitable for biosimilar work.

All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

For technical inquiry, please contact

Required Volume (µl) 20
Total Time (min) 140
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) + / -
Spike Recovery (%) -
Shelf Life (year) 1
Assay type Qualitative
Species Reactivity Human
Storage conditions Store at +4°C. Please refer to protocols.
Shipping conditions At room temperature
# File Action
Instructions For Use Download
Safety Data Sheet (SDS) Download

Publications with this drug

# File Action
Formica, María Lina, et al. "Novel hybrid lipid nanocapsules loaded with a therapeutic monoclonal antibody–Bevacizumab–and Triamcinolone acetonide for combined therapy in neovascular ocular pathologies." Materials Science and Engineering: C 119 (2020): 111398. Visit Link
de Redín, Inés Luis, et al. "In vivo efficacy of bevacizumab-loaded albumin in the treatment of colorectal cancer." Drug Delivery and Translational Research (2020): 1-11. Visit Link
Llabot, Juan M., et al. "In vitro characterization of new stabilizing albumin nanoparticles as a potential topical drug delivery system in the treatment of corneal neovascularization (CNV)." Journal of Drug Delivery Science and Technology 52 (2019): 379-385. Visit Link
Gregoritza, Manuel, et al. "Fabrication of antibody-loaded microgels using microfluidics and thiol-ene photoclick chemistry." European Journal of Pharmaceutics and Biopharmaceutics 127 (2018): 194-203. Visit Link
de Redín, Inés Luis, et al. "Human serum albumin nanoparticles for ocular delivery of bevacizumab." International journal of pharmaceutics 541.1-2 (2018): 214-223. Visit Link
Johannes Gojo, Robert Sauermann, Ursula Knaack, Irene Slave, Andreas Peyrl, Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies. Drugs R D 17:469-474, 2017. Visit Link
Gregoritza M, Messmann V, Abstiens K, Brandl FP, Göpferich AM, Controlled antibody release from degradable thermoresponsive hydrogels cross-linked by Diels-Alder chemistry, Biomacromolecules, Just Accepted Manuscript, 2017. Visit Link
Chen L., et al., Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus. Frontiers in Plant Science, 7 (1156), 2016. Visit Link
Bergen T.V., et al., Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery. Acta Ophthalmologica, 667-678, 2015. Visit Link
H. Akbulut, M. Ocal et al., The trough levels of bevacizumab significantly affects the outcome of the treatment in patents with metastatic colorectal cancer: A Turkish Oncology Group Study Visit Link
H. Akbulut, et al: The role of immune system on the efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC). Annals of Oncology, Volume 27, 2016, 7–11 October 2016, Copenhagen, Denmark. Visit Link
Evaluación de la relación exposición-respuesta de bevacizumab y de cetuximab en cáncer colorrectal metastásico y de cetuximab en cáncer de cabeza y cuello Silvia Peña Cabia Visit Link
La Spectrometrıe De Masse Applıquee A La Quantıfıcatıon Absolue Des Antıcorps Monoclonaux Therapeutıques En Mılıeu Plasmatıque Pour La Realısatıon D’etudes Pharmacocınetıques Pharmacodynamıques Dr.Rachel LEGERON-LIEUTENANT Visit Link
Radiomarcaje y biodistribución mediante SPECT-CT de nanopartículas de seroalbúmina humana con bevacizumab Dr. ROCÍO RAMOS MEMBRIVE Visit Link
Imaging probe for angiogenic activity in pulmonary arterial hypertension Paul B. YuMarcelo DICARLI Visit Link
The plant source recombinant humanized shellfish of a kind of optimization cuts down preparation method and the medical applications of monoclonal antibody, 于为常陈磊 Visit Link
Pangua C. et al. Mucus‑penetrating and permeation enhancer albumin‑based nanoparticles for oral delivery of macromolecules: Application to bevacizumab Visit Link